DEC 10, 2015 2:38 PM PST

TSRI Scientists Show How Drug Molecules Regulate a Medically Important Protein

A new study, led by scientists at The Scripps Research Institute (TSRI), shows how different pharmaceutical drugs hit either the “on” or “off” switch of a signaling protein linked to asthma, obesity and type 2 diabetes.

“The long-term goal is to use this knowledge to help discover new drugs,” said TSRI Professor David Millar, senior author of the study.
 
The Scripps Research Institute's Professor David Millar (left) and Research Associate Rajan Lamichhane were among the authors of the new paper.

The study, published recently in the journal Proceedings of the National Academy of Sciences, was a close collaboration between the Millar laboratory; the laboratory of Nobel Laureate Kurt Wüthrich, Cecil H. and Ida M. Green Professor of Structural Biology at TSRI; and the laboratory of Raymond C. Stevens, formerly of TSRI and now Provost Professor of Biological Sciences and Chemistry and director of The Bridge Institute at the University of Southern California (USC).

Crucial to Disease

The researchers focused on the beta-2 adrenergic receptor (β2AR), a protein that sits on the cell membrane, where it binds external molecules and sends signals to the inside of the cell. β2AR belongs to a class of proteins called G protein-coupled receptors (GPCRs). There are more than 800 known human GPCRs, and they are linked to conditions from heart disease to Parkinson’s disease and Huntington’s. β2AR is known to play a role in asthma, obesity and type 2 diabetes.

In fact, GPCRs are so crucial to disease that more than 35 percent of pharmaceuticals target these receptors.

In previous studies, scientists used a method called x-ray crystallography to catch “snapshots” of β2AR in its active and inactive forms. Although the static images provided insight into the protein’s structure, the scientists couldn’t show how frequently the receptor activated or how different drug molecules governed the time spent in each state.

“We wanted to go in-depth and look at the dynamics of this receptor in molecular detail using state-of-the-art single-molecule techniques,” said Rajan Lamichhane, research associate at TSRI and co-first author of the new study with Jeffrey J. Liu of the Max Planck Institute of Biochemistry (formerly of TSRI).

Surprise Findings

In the new study, the scientists incorporated β2AR in “nanodiscs,” small particles that mimic the native cell membrane but contain only a single receptor molecule. They tagged a section of the receptor with a fluorescent probe and monitored the fluorescence intensity over time in a sophisticated microscope system. The probe lit up when the receptor was inactive and went dim when active, giving the researchers a way to track activation in real time.

The researchers tested β2AR's reactions to formoterol, an anti-asthma drug known as an “agonist,” or activator, of β2AR signaling, and to the drug ICI 118,551, an inverse agonist known to suppress signaling.

The probe’s flickering revealed several crucial details about β2AR. First, the researchers found that the receptor naturally fluctuates between its active and inactive states in the absence of any drug—a phenomenon scientists had always suspected but had not been able to prove directly. Tracking the behavior of individual receptor molecules revealed these fluctuations for the first time and established how long the receptor stays in each state. Second, the presence of formoterol doesn’t just activate β2AR faster—it also stops β2AR from deactivating as quickly.

“That was a surprise,” said Millar, describing formoterol’s “twin” functions.

The researchers also saw that ICI 118,551 caused β2AR to deactivate more rapidly. Together, the findings explain why β2AR exhibits some signaling activity even in the absence of any drug molecules and why different drugs can either stimulate or inhibit signaling.

With the new single-molecule fluorescence technology in hand, the researchers said the next step is to find molecules that spark the same behavior as formoterol and ICI 118,551—perhaps molecules that could work on different GPCRs to affect different diseases.

In addition to Millar, Wüthrich, Stevens, Lamichhane and Liu, authors of the study, “Single-molecule view of basal activity and activation mechanisms of the G protein-coupled receptor β2AR,” were Goran Pljevaljcic of TSRI, now at BioNano Genomics; Kate L. White of USC; Edwin van der Schans of TSRI; and Vsevolod Katritch of TSRI and USC. See https://www.pnas.org/content/112/46/14254.abstract
This study was supported by a National Institutes of Health Road Map Initiative Grant (P50 GM073197.)
_________
FOR MORE INFORMATION
David Millar Biosketch
Millar Lab Website
PNAS paper
About the Author
  • The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists-including two Nobel laureates-work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
You May Also Like
DEC 16, 2020
Cell & Molecular Biology
A Close Connection Between Two Organelles is ID'ed
DEC 16, 2020
A Close Connection Between Two Organelles is ID'ed
The cell has many specialized components that perform specific functions, like an organelle called the endoplasmic retic ...
JAN 12, 2021
Immunology
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
JAN 12, 2021
Killer Control: Engineered Stem Cells Dodge Transplant Rejection
The first organ transplant—performed over 60 years ago—was a success because the donor and recipient were id ...
JAN 25, 2021
Microbiology
CrAssphages and the Manipulation of the Microbiome
JAN 25, 2021
CrAssphages and the Manipulation of the Microbiome
The advancement of genetic and computational tools has given us so much new information its opened up new research field ...
JAN 28, 2021
Cell & Molecular Biology
Gene Variants Affecting an Ion Channel Alter Parkinson's Disease Risk
JAN 28, 2021
Gene Variants Affecting an Ion Channel Alter Parkinson's Disease Risk
These variants can raise, or lower the risk of the disease, and now researchers have learned how they work.
FEB 09, 2021
Cell & Molecular Biology
Brain Cells Called Astrocytes Linked to Depression
FEB 09, 2021
Brain Cells Called Astrocytes Linked to Depression
Depression is thought to affect at least 264 million people of all ages worldwide, and the available treatment options d ...
FEB 15, 2021
Genetics & Genomics
Green Tea Boosts a DNA-Repairing, Tumor-Suppressing Protein
FEB 15, 2021
Green Tea Boosts a DNA-Repairing, Tumor-Suppressing Protein
Green tea has been lauded for its medicinal qualities, though it's been difficult to show that definitively. A new study ...
Loading Comments...